Abeona Therapeutics to Present at Multiple Upcoming Conferences

8 months ago

NEW YORK and CLEVELAND, May 19, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced that members of the management team will present at the following upcoming conferences:

Event: Cell & Gene Exchange
Panelist: President and CEO, Timothy J. Miller, Ph.D.
Panel: “Best Practices for Partnering with Disease Foundations and Patient Groups”
Date: Monday, May 22nd
Time: 3:15 PM ET

Presenter: President and CEO, Timothy J. Miller, Ph.D.
Abeona Company Presentation
Date: Tuesday, May 23rd
Time: 2:30 pm ET
Room: Atrium Ballroom
Location: Ronald Reagan Building, Washington, D.C.

Event: UBS Global Healthcare Conference
Presenter: Chief Operating Officer, Jeffrey B. Davis
Date: Tuesday, May 23rd
Time: 2:30 PM ET
Room: Ballroom V
Location: Grand Hyatt, New York, NY

Event: Neurotech Investing and Partnering Conference
Panelist: President and CEO, Timothy J. Miller, Ph.D.
Panel: “Targeting Orphan Diseases”
Date: Thursday, June 1st
Time: 3:45 PM PT
Location: Park Central Hotel, San Francisco, CA

Abeona Recent Highlights

ABO-102 gene therapy program for Sanfilippo syndrome Type A:
Abeona announced top-line data for Phase 1/2 MPS IIIA gene therapy trial at ASGCT
–Positive dose response in central nervous system with 60.7% +/- 8.8% reduction of disease-causing heparan sulfate GAG observed in Cohort 2 
–Reduction of disease manifestation observed in decreased liver volume of 14.81% (+/- 1.2%) 
–ABO-102 well-tolerated in six subjects through more than 1,100 days cumulative follow-up with no Serious Adverse Events
–Cohort 1 demonstrated stabilized or improved Leiter Nonverbal IQ scores at six months 
Abeona received regulatory approval to initiate ABO-102 gene therapy clinical trial in Australia for patients with MPS IIIA

EB-101 gene therapy program for severe form of Epidermolysis Bullosa:
Abeona provided an update for Phase 1/2a gene therapy to the Society for Investigative Dermatology Conference
–EB-101 demonstrated significant wound healing (defined as greater than 50% healed) in 100% of treated wounds (36/36) at 3 months; 89% (32/36) at 6 months, 83% (20/24) at 12 months, 88% (21/24) at 24 months and 100% (6/6) at 36 months post-administration
–Clinical endpoints supported by data from Natural History Study observations from 1,436 wounds in 128 patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Abeona was granted Orphan Drug Designation for EB-101 in Epidermolysis Bullosa by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein therapy pipeline, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit

Investor Contact:
Christine Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212)-786-6212

Media Contact:
Andre’a Lucca
Vice President, Communications & Operations
Abeona Therapeutics Inc.
+1 (212)-786-6208

Stock Information

Investor Toolkit


Follow this blog

Get every new post delivered right to your inbox.

Email address